Evidence from genetic and clinical studies supports the premise that X chromosome dosage, inactivation patterns, and heterochromatin formation (Barr bodies) play a substantial role in shaping the phenotypic variations observed in Turner syndrome and related conditions.
The retrieved literature extensively covers how X chromosome dosage anomalies, X-inactivation mechanics, and heterochromatin dosage (Barr bodies) directly impact phenotypic differences and disease risks, including Turner syndrome presentations and mosaicism. Papers 3, 5, and 11 provide direct or closely related mechanistic backing for the claim, and no papers refute it.